AstraZeneca has pushed the boundaries of science and helped millions of patients with respiratory disease. Early access to AstraZeneca investigational medicinal products . Respiratory & Immunology. Read about our latest progress in cardiovascular, respiratory and other core therapy areas. AstraZeneca has pushed the boundaries of science and helped millions of patients with respiratory disease. We are advancing a pipeline of inhaled and biologic treatments, drug combinations and devices, and other therapies that aim to transform disease management. We recognise that there are circumstances where patients with serious or life-threatening diseases have exhausted all available therapeutic options and may not be eligible to enrol in one of our clinical trials. Apologies for any inconvenience.© AstraZeneca 2020. What science can do. We know now that a process called eosinophilic immune dysfunction may be responsible for the eosinophil recruitment and activation that is driving these diseases. Backed by a growing body of evidence, we’re committed to advancing the understanding of the role of eosinophils in inflammatory diseases, with the aim to improve diagnosis, patient referrals and timely, appropriate treatment.terbutaline in a dry powder inhalerbudesonide inhalation suspensionbudesonide/glycopyrronium/formoterol fumarateExplore the role of eosinophils across Respiratory & ImmunologyClick ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.Senior Vice President, Global Respiratory & ImmunologySenior Vice President and Global Head of Respiratory & Immunology Late Stage Development, BioPharmaceuticals R&DAs the world adjusts to a new paradigm, and with the long-term impacts of the COVID-19 pandemic still unclear, it is essential that we maintain focus on the people we serve.glycopyrronium/formoterol fumarateResearch into the underlying drivers of SLE is supporting the potential development of new treatment options for this complex autoimmune condition.By following the science in immunology we are also gaining new insights into how immune processes may play a role in a broad range of conditions.You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.AstraZeneca provides this link as a service to website visitors. Join AstraZeneca Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals. Senior Vice President and Head of Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&DAt AstraZeneca, we’re continuing to better understand the important role of eosinophils as key effector cells in a range of potentially devasting inflammatory diseases, in which elevated eosinophils are a direct cause or are thought to play a critical role. The disease areas we’re targeting include rheumatology (including type 1 interferon-driven diseases such as lupus), dermatology, gastroenterology and systemic eosinophilic-driven diseases. Please refer to your approved national product label (SmPC) for current product information. AstraZeneca has completed its previously announced transaction to acquire the rights to Actavis' branded respiratory business in the US and Canada. Respiratory biologics is a key focus for AstraZeneca, and we are expanding our team with a number of exciting opportunities. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. FASENRA is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.Unfortunately, you are using an unsupported browser. We are advancing a pipeline of inhaled and biologic treatments, drug combinations and devices, and other therapies that aim to transform disease management. At AstraZeneca, science is at the core of everything we do. Please use Google Chrome 52.0 or Internet Explorer 11 or later. You are about to access AstraZeneca historic archive material. Currently, our respiratory biologics portfolio includes one recently approved medicine for the treatment of severe eosinophilic asthma, with numerous regulatory decisions pending in additional countries across the globe. AstraZeneca Careers. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. All rights reserved.Duaklir▼(aclidinium/formoterol fumarate dehydrate) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).Our 40-year heritage in respiratory medicines is just the beginning of our story. Our 40-year heritage in respiratory medicines is just the beginning of our story. AstraZeneca is following the science of common pathways and underlying disease drivers from respiratory disease into immunology-driven disease areas. Infection and Vaccines. Neuroscience.